Legal Liabilities in Clinical Trials

  • Ian C. Dodds-Smith
Chapter

Abstract

There is a voluminous literature on legal issues in clinical research and, more particularly, the relationship between law and ethics. Medicine is international but the law often varies from country to country. This chapter must, therefore, inevitably be less than comprehensive and the approach will essentially be to indicate how the main issues are addressed by English law, making comparisons with other jurisdictions only where these are particularly striking or relevant to the likely development of English and European Community law.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    The Nuremberg Code; Trials of War Criminals before the Nuremberg Tribunals (1949). No. 10, Vol. 2, pp. 181–2, Washington D.C., US Government Printing OfficeGoogle Scholar
  2. 2.
    Regan, L. J. (1956). Doctor and Patient and the Law, 3rd edn, MosbyGoogle Scholar
  3. 3.
    65/65/EEC (as amended), OJ No. 22, 09.02.65, p. 369Google Scholar
  4. 4.
    Medicines Act (1968). Chapter 67, HMSO, LondonGoogle Scholar
  5. 5.
    See English and Scottish Standing Medical Advisory Committee and Hansard, 15 February 1968, at p. 1608Google Scholar
  6. 6a.
    See HM(68)33 and Supervision of the Ethics of Clinical Research Investigations and Fetal Research, HSC (IS) 153, Department of Health, 1975Google Scholar
  7. 6b.
    Draft Guidelines for Local Research Ethics Committees. Department of Health, October, 1989Google Scholar
  8. 7.
    Nature, 307, 09.02.84, and Daily Telegraph, 31.05.84Google Scholar
  9. 8.
    Orme, M. et al. (1989). Healthy volunteer studies in Great Britain. Br. J. Clin. Pharm., 27, 125–33; and Spiers, C. J. and Griffin, J. P. (1983). A survey of the first year of the operation of the new procedure affecting the conduct of clinical trials in the UK. Br. J. Clin. Pharm., 15, 649–55CrossRefGoogle Scholar
  10. 9.
    Federal German Pharmaceutical Law, dated 24.08.76, BGBle.1.1976, p. 2445; see Sections 40–42Google Scholar
  11. 10.
    Control of Clinical Trials Act, Number 28 of 1987. The Stationery Office, DublinGoogle Scholar
  12. 11.
    French law on the protection of persons undergoing biochemical research, No. 88-1138-1988, Dec 20thGoogle Scholar
  13. 12.
    Arpaillange, et al. (1985). Proposal for ethical standards in therapeutic trials, Br. Med. J., 291, 887CrossRefGoogle Scholar
  14. 13.
    EEC/CPMP. Working Party on Efficiency of Drugs, July 3, 1987, III/411/87/EN-RevGoogle Scholar
  15. 14.
    Hvidberg, E. F. (1988). Presentation to Interscience Conference on Conduct of Clinical Trials, CopenhagenGoogle Scholar
  16. 15.
    Good Clinical Practice for Trials or Medicinal Products in the European Community. European Commission, III/3976/88-EN Rev 1, 17.02.89Google Scholar
  17. 16.
    World Medical Association. Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. Adopted 1964 and revised in Tokyo (1975) and Venice (1983)Google Scholar
  18. 17.
    Supply of Goods and Services Act (1982). Chapter 29, HMSO, LondonGoogle Scholar
  19. 18.
    The Unfair Contract Terms Act (1977). Chapter 50, HMSO, LondonGoogle Scholar
  20. 19.
    Association of British Pharmaceutical Industry, Circular 87/89Google Scholar
  21. 20.
    For an explanation of the general principles see Donoghue v. Stevenson (1932), A.C. 562 H.L.; and Vacwell Engineering Co Ltd v BDH Chemicals Ltd (1971), 1QB 88Google Scholar
  22. 21.
    Dukes, M. N. G. and Swartz, B. (1988). Responsibility for Drug-induced Injury, Elsevier, p. 299Google Scholar
  23. 22.
    Cynat Products Ltd v. Landbuild (Investment & Property) Ltd (1984), 3 All ER 513Google Scholar
  24. 23.
    Directive 85/374/EEC, OJ No. L 210/29Google Scholar
  25. 24.
    Consumer Protection Act (1987). Chapter 43, HMSO, LondonGoogle Scholar
  26. 25.
    Implementation of the E.C. Directive on Product Liability. An Explanatory and Consultative Note, Department of Trade, Nov. 1985, at ¶56, p. 14Google Scholar
  27. 26.
    Directive 85/374/EEC, Supra at 23, Article 7(e)Google Scholar
  28. 27.
    Consumer Protection Act, Supra at 24, Section 4(1)(e)Google Scholar
  29. 28.
    Consumer Protection Act, Supra at 24, Section 10(7)(e)Google Scholar
  30. 29.
    Sidaway v. Bethlem Royal Hospital Governors (1985), AC 871, applying Bolam v. Friern Hospital Management Committee (1957), 2 All ER 118Google Scholar
  31. 30.
    Federal German Pharmaceutical Law, Supra at 9, Section 40(1.4)Google Scholar
  32. 31.
    Consumer Protection Act, Supra at 24, Section 3(3)Google Scholar
  33. 32.
    Collins v. Wilcock (1984), 1 W.L.R. 1172Google Scholar
  34. 33.
    Freeman v. Home Office (No. 2) (1984), QB 524Google Scholar
  35. 34.
    The Report of the Committee to Investigate Medical Experiments on Staff Volunteers (1970). Association of the British Pharmaceutical Industry, ¶3.3. (Updated as Guidelines for Medical Experiments on Non-patient Volunteers, 1984)Google Scholar
  36. 35.
    Wilson v. Pringle (1987), QB 237, 253Google Scholar
  37. 36.
    Re F. (1989) 2 WLR 1025Google Scholar
  38. 37.
    Freeman v. Home Office (No. 2), Supra at 33Google Scholar
  39. 38.
    Declaration of Helsinki, Supra at 16, see Section I(ii)Google Scholar
  40. 39.
    Family Law Reform Act (1969), S.8(l), Chapter 36; and Gillick v. West Norfolk and Wisbech Area Health Authority and the Department of Health (1985), 2 All ER 402Google Scholar
  41. 40.
    Kennedy, I. The Patient on the Clapham Omnibus, MLR, Vol. 47, 454Google Scholar
  42. 41.
    Dworkin, G. (1978). Arch. Dis. Child., 53, 443PubMedCentralCrossRefPubMedGoogle Scholar
  43. 42.
    Report of the Medical Research Council of 1962–63 entitled Responsibility in Investigations on Human Subjects, Cmnd 2382, HMSO, LondonGoogle Scholar
  44. 43.
    HSC (15) 153, Department of Health, Supra at 6Google Scholar
  45. 44.
    Medicines Commission Advice to Health Ministers on Healthy Volunteer Studies (1987), HMSO, LondonGoogle Scholar
  46. 45.
    See Report of the Medical Research Council, Supra at 42 and TvT 1988 Fam. 62Google Scholar
  47. 46.
    In Re B. (a minor) (wardship: sterilisation) 1988, AC199Google Scholar
  48. 47.
    In Re F., Supra at 36Google Scholar
  49. 48.
    Control of Clinical Trials Act (1987), Supra at 10, see S.9(7)Google Scholar
  50. 49.
    Medicines Commission, Supra at 44Google Scholar
  51. 50.
    Sidaway, Supra at 29Google Scholar
  52. 51.
    Unfair Contract Terms Act (1977), Chapter 50, Supra at 18Google Scholar
  53. 52.
    Hatcher v. Black (1954) The Times, July 2ndGoogle Scholar
  54. 53.
    Canterbury v. Spence (1972), 464. F 2d 772; and Reibl v. Hughes (1981), 114 DLR (3d)1Google Scholar
  55. 54.
    Sidaway, Supra at 29; Gold v. Haringey Health Authority (1987), 2 All ER at 888; Blyth v. Bloomsbury Health Authority (1987), The Times, Feb 11, CAGoogle Scholar
  56. 55.
    Sidaway, Supra at 29Google Scholar
  57. 56.
    Food and Drug Administration Rules and Regulations Part 56 (1981). Federal Reporter, 46 (17), Jan 27thGoogle Scholar
  58. 57.
    Halsuska v. University of Saskatchewan et al., 1965, 52 WWR 616Google Scholar
  59. 58.
    Gold v. Haringey Health Authority, Supra at 54Google Scholar
  60. 59.
    Blyth v. Bloomsbury Health Authority, Supra at 54Google Scholar
  61. 60.
    EEC/CPMP Working Party Guidelines, Supra at 13Google Scholar
  62. 61.
    Fost, N. (1979). Sounding board. Consent as a barrier to research. New Engl. J. Med., 300, 1272–3CrossRefPubMedGoogle Scholar
  63. 62.
    See, for instance, The Observer, Editorial of 09.10.88Google Scholar
  64. 63.
    For a general discussion see Vere, D. (1981). Editorial, J. Roy. Soc. Med., 74, Feb; and Report of Cancer Research Campaign Working Party (1983). Br. Med. J., 286, April 2ndGoogle Scholar
  65. 64.
    Feinstein, A. R. (1980). Eur. J. Clin. Pharm., 17, 1–4CrossRefGoogle Scholar
  66. 65.
    Control of Clinical Trials Act, Supra at 10, see S9(4)(d)Google Scholar
  67. 66.
    EEC/CPMP Working Party Guidelines, Supra at 10Google Scholar
  68. 67.
    Gilbert, J. (1988). Letter, I.M.E. Bulletin, Oct, p. 10Google Scholar
  69. 68.
    Sections 40(2) and 41(6) Federal German Pharmaceutical Law, Supra at 9Google Scholar
  70. 69.
    HSC (15) 153, Supra at 6Google Scholar
  71. 70.
    Guidelines on the Practice of Ethics Committees in Medical Research (1984). Royal College of Physicians, LondonGoogle Scholar
  72. 71.
    The Medicines (Exemption from Licences) (Clinical Trials) Order SI 1981, No. 164Google Scholar
  73. 72.
    Medicines Commission, Supra at 44Google Scholar
  74. 73.
    FDA Rules, Supra at 56Google Scholar
  75. 74.
    S8(4) Control of Clinical Trials Act, Supra at 10. In contrast, in Denmark until March 1989, trials could begin before ethics committees had completed their review, which often took place after trials were completed! (See Scrip, No. 1389, 24.02.89)Google Scholar
  76. 75.
    Title III of new French law, Supra at 11Google Scholar
  77. 76.
    See for instance Peabody Donation Fund v. Sir Lindsay Parkinson & Co Ltd (1985), AC 210, and Rowling v. Takaro Properties Ltd (1988) AC 473Google Scholar
  78. 77.
    See for instance the Opren (benoxaprofen) litigation settled before trial—Davies v. Eli Lilly and Others (1988), unreportedGoogle Scholar
  79. 78.
    S.40(3) Federal German Pharmaceutical Law, Supra at 9Google Scholar
  80. 79.
    S10 Control of Clinical Trials Act, Supra at 10Google Scholar
  81. 80.
    See ¶1339 of Royal Commission on Civil Liability and Compensation for Personal Injury, March, 1978, Cmnd 7054, HMSO, London; and letter (unpublished) of October, 1973 from Chief Medical Officers of Department of Health to President of Royal College of Physicians, LondonGoogle Scholar
  82. 81.
    Royal Commission, Supra at 80Google Scholar
  83. 82.
    Medical Research: Civil Liability and Compensation for Personal Injury (1980). The Ciba FoundationGoogle Scholar
  84. 83.
    ABPI Report, Supra at 42Google Scholar
  85. 84.
    ABPI Guidelines for Medical Experiments in Non-patient Human Volunteers (1988). MarchGoogle Scholar
  86. 85.
    ABPI Guidelines (1983). Clinical Trials—Compensation for Medicine-induced Injury, AugustGoogle Scholar
  87. 86.
    Medicines Commission, Supra at 44Google Scholar
  88. 87.
    Legal Liability and the Supply of Investigational Drugs (1986). ABPI Circular No. 494/86Google Scholar
  89. 88.
    Diamond, A. L. and Laurence, D. R. (1983). Br. Med. J., Sept 3rd, p. 676Google Scholar
  90. 89.
    Research on Healthy Volunteers (1986). A Report of the Royal College of Physicians, LondonGoogle Scholar
  91. 90.
    Medicines Commissions, Supra at 44, see ¶6.16Google Scholar
  92. 91.
    FDA Rules, Supra at 56, S.50.25(a)(b)Google Scholar
  93. 92.
    Ciba Foundation, Supra pp. 9 and 11Google Scholar

Copyright information

© The editors and contributors 1990

Authors and Affiliations

  • Ian C. Dodds-Smith
    • 1
  1. 1.McKenna & Co.LondonUK

Personalised recommendations